Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas

HSP90, a highly conserved molecular chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma. However, HSP90 inhibitors currently in clinical trials are short-acting, have unacceptable toxicities, or are unable to cross the blood-brain barrier (BBB). We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2017-10, Vol.23 (20), p.6215-6226
Hauptverfasser: Canella, Alessandro, Welker, Alessandra M, Yoo, Ji Young, Xu, Jihong, Abas, Fazly S, Kesanakurti, Divya, Nagarajan, Prabakaran, Beattie, Christine E, Sulman, Erik P, Liu, Joseph, Gumin, Joy, Lang, Frederick F, Gurcan, Metin N, Kaur, Balveen, Sampath, Deepa, Puduvalli, Vinay K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!